ESPR
Esperion Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-2.05
P/S
1.35
EV/EBITDA
14.70
DCF Value
$-63.10
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.4%
Operating Margin
15.0%
Net Margin
-5.6%
ROE
5.6%
ROA
-4.9%
ROIC
23.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $168.4M | $61.8M | $0.22 |
| FY 2025 | $403.1M | $-22.7M | $-0.11 |
| Q3 2025 | $87.3M | $-31.3M | $-0.16 |
| Q2 2025 | $82.4M | $-12.7M | $-0.02 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.17
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.